Short answer
ANAVEX LIFE SCIENCES CORP. (AVXL) filed its Q2 2026 10-Q quarterly report on Aug 28, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- $8M
- +159.1% YoY · +246.6% QoQ
- EPS (diluted)
- $0.09
- +156.3% YoY · +250.0% QoQ
Source: XBRL data from the ANAVEX LIFE SCIENCES CORP. (AVXL) Q2 2026 10-Q on SEC EDGAR. USD.
ANAVEX LIFE SCIENCES CORP. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged year over year; no products approved for commercial sale
- Profitability not stated; clinical-stage company with no commercial revenue
- Lead compound ANAVEX 2-73 prioritized for early Alzheimer’s disease, Rett syndrome, and Fragile X syndrome
- Other assets ANAVEX 3-71, 1-41, and 1066 de-prioritized; development paused
- Near-term focus on FDA engagement and data-driven regulatory strategy; additional funding or partnerships needed for paused assets
Risk Factors
- Former CEO termination for Cause triggered potential litigation, inquiries, investigations, and enforcement actions
- Arbitration demand filed June 2026 alleging wrongful termination
- New York Supreme Court action filed July 2026 against four independent directors
- FDA, SEC, and Nasdaq proceedings risk management distraction and reputational harm
- Investor, patient, and partner confidence loss could pressure operations and stock price
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ANAVEX LIFE SCIENCES CORP. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.